1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease - Drugs In Development, 2022, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 8, 59, 85, 6, 293, 153 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 56 and 18 molecules, respectively.
Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Parkinson's Disease - Overview
- Parkinson's Disease - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Parkinson's Disease - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Parkinson's Disease - Companies Involved in Therapeutics Development
- Parkinson's Disease - Drug Profiles
- Parkinson's Disease - Dormant Projects
- Parkinson's Disease - Discontinued Products
- Parkinson's Disease - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Parkinson's Disease, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Parkinson's Disease - Dormant Projects, 2022
- Parkinson's Disease - Discontinued Products, 2022
- Number of Products under Development for Parkinson's Disease, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 1st Bio Therapeutics Inc
- 2N Pharma ApS
- 3Z ehf
- 4D Pharma Plc
- Abaxy Sprl
- Abaxys Therapeutics SA
- AbbVie Inc
- Abfero Pharmaceuticals Inc
- Abivax SA
- ABL Bio Inc
- AC Immune SA
- Accure Therapeutics SL
- AceLink Therapeutics Inc
- Acelot Inc
- AcureX Therapeutics Corp
- Addex Therapeutics Ltd
- Adhera Therapeutics Inc
- Adicet Bio Inc
- Aeterna Zentaris Inc
- AevisBio Inc
- AgoneX Biopharmaceuticals Inc
- Akome Biotech Ltd
- Alan Laboratories Inc
- Alar Pharmaceuticals Inc
- Alector Inc
- Alexza Pharmaceuticals Inc
- Alkahest Inc
- AlphaCognition Inc
- Alsonex Pty Ltd
- Alterity Therapeutics Ltd
- AltPep Corp
- AlzeCure Pharma AB
- Amathus Therapeutics Inc
- Amneal Pharmaceuticals Inc
- Anavex Life Sciences Corp
- ANLBio Co Ltd
- Annovis Bio Inc
- Aoxing Pharmaceutical Company Inc
- Appello Pharmaceuticals Inc
- Aprinoia Therapeutics Inc
- AptaBio Therapeutics Inc
- Aptamer Sciences Inc
- Aranda Pharma Ltd
- AriBio
- ArmaGen Inc
- Arrien Pharmaceuticals LLC
- Artizan Biosciences Inc
- ArunA Bio Inc
- Arvinas Inc
- Asceneuron SA
- Asdera LLC
- Asha Therapeutics LLC
- Ashvattha Therapeutics LLC
- Asklepios BioPharmaceutical Inc
- Aspen Neuroscience Inc
- Astellas Pharma Inc
- AstraZeneca Plc
- Astrogen Ltd
- Atalanta Therapeutics Inc
- Athira Pharma Inc
- Atlantic Healthcare Plc
- AUM LifeTech Inc
- Autifony Therapeutics Ltd
- Autotelic Bio Inc
- Avicanna Inc
- Axial Therapeutics Inc
- Azymus Therapeutics Inc
- B&A Therapeutics
- BCWorld Pharm Co Ltd
- Beech Tree Labs Inc
- Beijing Toll Biotech Co Ltd
- Belief Biomed Inc
- Belrose Pharma Inc
- BenevolentAI Ltd
- Berg LLC
- Better Life Pharmaceuticals Inc
- Bial - Portela & Ca SA
- Bio-Modeling Systems SAS
- Bio-Pharm Solutions Co Ltd
- BioArctic AB
- Bioasis Technologies Inc
- Biogen Inc
- Bionaut Labs Inc
- Biorchestra Co Ltd
- BioVie Inc
- Bisichem Co Ltd
- Blackfynn Inc
- Blue Therapeutics Inc
- BlueRock Therapeutics LLC
- Bopin (Shanghai) Biomedical Technology Co Ltd
- BrainEver SAS
- BrainStorm Cell Therapeutics Inc
- Bristol-Myers Squibb Co
- Britannia Pharmaceuticals Ltd
- Bukwang Pharmaceutical Co Ltd
- C4 Therapeutics Inc
- C4X Discovery Holdings Plc
- Calico Life Sciences LLC
- Cantabio Pharmaceuticals Inc
- Canvax Biotech SL
- Caraway Therapeutics Inc
- Carmot Therapeutics Inc
- Carna Biosciences Inc
- Casma Therapeutics Inc
- Celavie Biosciences LLC
- Celeris Therapeutics Inc
- CellCure
- Cellivery Therapeutics Inc
- Celros Biotech Co Ltd
- Cerecin Pte Ltd
- CereSpir Inc
- Cerevance Inc
- Cerevel Therapeutics Holdings Inc
- CHA Biotech Co Ltd
- Chamishi Therapeutics Inc
- Chase Therapeutics Corp
- Chiesi Farmaceutici SpA
- Chimerna Therapeutics Inc
- CholesteniX Ltd
- Chongqing Pharmaceutical Research Institute Co Ltd
- Ci Therapeutics
- Circadian Therapeutics
- Clayton Biotechnologies Inc
- Clene Inc
- Clevexel Pharma SA
- Clexio Biosciences Ltd
- Coave Therapeutics
- Cogentis Therapeutics Inc
- Cognition Therapeutics Inc
- Collaborative Medicinal Development LLC
- Contera Pharma ApS
- Convalesce Inc
- Copernicus Therapeutics Inc
- Corium Inc
- Coya Therapeutics Inc
- Creative Medical Technology Holdings Inc
- Crossject SA
- CuraSen Therapeutics Inc
- Curemark LLC
- CuroNZ Ltd
- Cypralis Ltd
- Dadang & BIO Co Ltd
- DanPET AB
- Deep Genomics Inc
- DegenRx BV
- Delpor Inc
- Denali Therapeutics Inc
- Denovo Biopharma LLC
- DermaXon LLC
- Diffusion Pharmaceuticals Inc
- Dina Pharmaceuticals Inc
- Dizlin Pharmaceuticals AB
- DongKoo Bio & Pharma Co Ltd
- DR.Noah Biotech Inc
- E-scape Bio Inc
- Easywell Biomedical Inc
- EHL Bio Co Ltd
- Eikonoklastes Therapeutics Inc
- Eisai Co Ltd
- Eli Lilly and Co
- EmendoBio Inc
- Emerald Health Sciences Inc
- Emyria Ltd
- ENCEFA
- Enveda Biosciences Inc
- ES Therapeutics LLC
- Evgen Pharma Plc
- Exegenesis Bio Inc
- Eyam Vaccines and Immunotherapeutics Ltd
- F. Hoffmann-La Roche Ltd
- FibroGenesis LLC
- Forest Hills Partners Hong Kong Ltd
- Fortuna Fix Inc
- Fulcrum Therapeutics Inc
- Gain Therapeutics Inc
- GB Sciences Inc
- Gene Therapy Research Institution Co Ltd
- Generoath Co Ltd
- Genervon Biopharmaceuticals LLC
- GenKyoTex SA
- Genmab AS
- Gismo Therapeutics Inc
- Glaceum Inc
- Global BioLife Inc Ltd
- GNT Pharma Co Ltd
- GraySpace Therapeutics Inc
- Grespo AB
- Guangdong East Sunshine Pharmaceutical Co Ltd
- Guangzhou Dazhou Biomedical Technology Co Ltd
- Guangzhou DM Intelligence Ltd
- Guangzhou Henovcom Bioscience Co Ltd
- Guangzhou Magpie Pharmaceutical Co Ltd
- H. Lundbeck AS
- Halia Therapeutics Inc
- Hangzhou Zede Pharmaceutical Technology Co Ltd
- Hebei Newtherapy BIo-Pharma Technology Co Ltd
- Help Therapeutics
- Herantis Pharma Plc
- Herophilus
- Hillhurst Biopharmaceuticals Inc
- HLB Pharmaceutical Co Ltd
- Hong Kong WD Pharmaceutical Co Ltd
- Hope Biosciences LLC
- Hopstem Biotechnology LLC
- Ibex Biosciences LLC
- Icagen Inc
- ICB International Inc
- iCELL Biotechnology Co Ltd
- Icure Pharmaceutical Inc
- Ildong Pharmaceutical Co Ltd
- Ilyang Pharmaceutical Co Ltd
- Imago Pharmaceuticals Inc
- Immune Modulation Inc
- Immungenetics AG
- Impel Pharmaceuticals Inc
- Imstem Biotechnology Inc
- Inexia Ltd
- Inhibikase Therapeutics Inc
- Innervace Inc
- InnoMedica Holding AG
- InnoPharmaScreen Inc
- International Stem Cell Corp
- Intra-Cellular Therapies Inc
- Invisio Ltd
- Io Therapeutics Inc
- Ionis Pharmaceuticals Inc
- Ipsen SA
- iRegene Therapeutics Co Ltd
- IRLAB Therapeutics AB
- Jazz Pharmaceuticals Plc
- Jeil Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Junaxo Inc
- Kainos Medicine Inc
- Kallyope Inc
- Kariya Pharmaceuticals IVS
- Kashiv BioSciences LLC
- Keapstone Therapeutics Ltd
- KeifeRx LLC
- Kissei Pharmaceutical Co Ltd
- Korea Pharma Co Ltd
- Kyowa Kirin Co Ltd
- Lan Sheng Biomedicine Suzhou Co Ltd
- Lauren Sciences LLC
- Lead Discovery Center GmbH
- Lennham Pharmaceuticals Inc
- LISCure Biosciences Co Ltd
- Living Cell Technologies Ltd
- Longevity Biotech Inc
- Lucy Therapeutics Inc
- Luye Pharma Group Ltd
- Lys Therapeutics SAS
- Lysogene SAS
- MD Healthcare Inc
- MegaNano BioTech Inc
- MeiraGTx Holdings Plc
- Mercaptor Discoveries Inc
- Merck & Co Inc
- Metabolic Solutions Development Company LLC
- MetiMedi Pharmaceuticals Co Ltd
- MimeTech Srl
- Minerva Neurosciences Inc
- Mission Therapeutics Ltd
- Mitochon Pharmaceuticals Inc
- Mitoconix Bio Ltd
- MitoDys Therapeutics Ltd
- MitoImmune Therapeutics Inc
- Mitokinin LLC
- Mitsubishi Tanabe Pharma Corp
- Molomics Biotech SL
- Montisera Ltd
- Motac Neuroscience Ltd
- MRM Health NV
- MThera Pharma Co Ltd
- Muna Therapeutics ApS
- Myodopa Ltd
- Nanomerics Ltd
- Neonc Technologies Inc
- Netherlands Translational Research Center BV
- NeuExcell Therapeutics Inc
- Neuracle Science Co Ltd
- Neuraly Inc
- Neuramedy Co Ltd
- Neuren Pharmaceuticals Ltd
- Neuro Vigor LLC
- Neurochlore
- Neurodon LLC
- Neuroene Therapeutics LLC
- Neuron23 Inc
- Neurona Therapeutics Inc
- NeuroNascent Inc
- NeuroPn Therapeutics LLC
- Neuropore Therapies Inc
- NeuroSense Therapeutics Ltd
- Neuvivo Inc
- New Amsterdam Sciences Inc
- New Biotic Inc
- New World Laboratories Inc
- Newron Pharmaceuticals SpA
- Nexmos Inc
- Nine Square Therapeutics Inc
- Nitrase Therapeutics Inc
- nLife Therapeutics SL
- NLS Pharmaceutics AG
- Nostrum Biodiscovery SL
- Notitia Biotechnologies Co
- Novartis AG
- Novo Nordisk AS
- NRG Therapeutics Ltd
- NTZ Lab Ltd
- Nuravax Inc
- NurrOn Pharmaceuticals Inc
- NutriBand Inc
- NysnoBio LLC
- OccamzRazor
- Ohara Pharmaceutical Co Ltd
- Omeros Corp
- Oncodesign SA
- Origami Therapeutics Inc
- Orpheris Inc
- Oryzon Genomics SA
- Oxyrane Belgium NV
- Parkure Ltd
- Peptron Inc
- Pfizer Inc
- Pharma Two B Ltd
- PharmaKure Ltd
- PharmaTher Holdings Ltd
- PharmatrophiX Inc
- Pharmaxis Ltd
- Phoenix Biotechnology Inc
- Phoenix Life Sciences International Ltd
- Pike Therapeutics Inc
- PK Biosciences Corp
- Plex Pharmaceuticals Inc
- Polaryx Therapeutics Inc
- PolyCore Therapeutics LLC
- Praxis Precision Medicines Inc
- Prazer Therapeutics
- PRG S&Tech Inc
- Priavoid GmbH
- Prilenia Therapeutics Development Ltd
- Primary Peptides Inc
- Proclara Biosciences Inc
- Progenra Inc
- ProMIS Neurosciences Inc
- Promius Pharma LLC
- Prosetta Biosciences Inc
- Prothena Corp Plc
- Prous Institute for Biomedical Research SA
- Psy Therapeutics Inc
- PTC Therapeutics Inc
- PureIMS BV
- Quince Therapeutics Inc
- Reata Pharmaceuticals Inc
- reMYND NV
- ReNeuron Group Plc
- ResQ Biotech
- Retrotope Inc
- Revalesio Corp
- Reven Holdings Inc
- Reviva Pharmaceuticals Inc
- Rionis
- S.Biomedics Co Ltd
- Sage Therapeutics Inc
- Samus Therapeutics Inc
- SanBio Co Ltd
- Saniona AB
- Sanofi
- SciNeuro Pharmaceuticals
- SeaBeLife Spas
- Seelos Therapeutics, Inc.
- Senda Biosciences Inc
- Seneb BioSciences Inc
- Sengenics Corp Pte Ltd
- Serina Therapeutics Inc
- Shanghai Green Valley Pharmaceutical Co Ltd
- Shanghai Leado Pharmaceutical Technology Co Ltd
- Shape Therapeutics Inc
- Shenox Pharmaceuticals LLC
- Shift Bioscience Ltd
- Shijiazhuang Yiling Pharmaceutical Co Ltd
- SignPath Pharma Inc
- Sihuan Pharmaceutical Holdings Group Ltd
- Silo Pharma Inc
- Silver Creek Pharmaceuticals Inc
- Sinfonia Biotherapeutics Inc
- Sinopia Biosciences Inc
- SNLD Ltd
- SOLA Biosciences LLC
- SOM Biotech SL
- Sorrento Therapeutics Inc
- SparkBioPharma Inc
- SQZ Biotechnologies Co
- Stada Arzneimittel AG
- Standigm Inc
- STATegics Inc
- Stealth BioTherapeutics Corp
- Stellate Therapeutics Inc
- Sumitomo Chemical Co Ltd
- Sumitomo Pharma Co Ltd
- Sun Pharma Advanced Research Company Ltd
- Sunovion Pharmaceuticals Inc
- Supernus Pharmaceuticals Inc
- Suven Life Sciences Ltd
- Synapss Therapeutics Inc
- Synaptogenix Inc
- Synthonics Inc
- Taho Pharmaceuticals Ltd
- Taiwan Mitochondrion Applied Technology Co Ltd
- Takeda Pharmaceutical Co Ltd
- Tarus Therapeutics Inc
- TauRx Therapeutics Ltd
- Techfields Pharma Co Ltd
- TechnoPhage SA
- Teijin Pharma Ltd
- Teikoku Pharma USA Inc
- Tempero Bio
- Tessara Therapeutics Pty Ltd
- Teva Pharmaceutical Industries Ltd
- The Greater Cannabis Company Inc
- Therapeutic Solutions International Inc
- Trailhead Biosystems Inc
- Tranquis Therapeutics Inc
- TreeFrog Therapeutics SAS
- Treventis Corp
- Triplet Therapeutics Inc
- UCB SA
- UniQure NV
- Vanda Pharmaceuticals Inc
- Vanqua Bio Inc
- Varinel Inc
- Vaxxinity Inc
- Verge Genomics
- Videns Incorp Ltd
- Vimgreen Pharma Ltd
- Vincere Biosciences Inc
- Vitro Biopharma Inc
- Vivifi Biotech Ltd
- Vivozon Inc
- Vivreon Biosciences LLC
- Voyager Therapeutics Inc
- Vyant Bio Inc
- Whan In Pharm Co Ltd
- Wren Therapeutics Ltd
- XellSmart Biomedical (Shanghai) Co Ltd
- Xoc Pharmaceuticals Inc
- Yuhan Corp
- Yumanity Therapeutics Inc
- Zhittya Genesis Medicine Inc
- ZyVersa Therapeutics Inc
